Podcasts about improving outcomes

When you listen to an orchestra, the blending of numerous instruments into a harmonious melody is what makes the music truly captivating. While a single instrument can sound wonderful on its own, there is something profoundly powerful and beautiful about the orchestral approach. This concept applies to our school systems as well, where we refer to it as systemic synergy.Welcome back to our esteemed hosts, Kim Yaris, M.Ed., Content Creator/Researcher, and Dr. Jennifer Chevalier, Director of Funding. Together, they offer a sneak peek into what we can expect from this summer's Research Conversations and help define systemic synergy, the main theme of this season. This episode introduces the first of many tools designed to help your school district enhance outcomes for everyone through systemic synergy. Don't miss out on this educational episode!Don't forget to like and subscribe, and turn on those bell notifications so you don't miss our next episode!To take advantage of the tool to help your school's vision click on this link:Learn more about academics here:https://www.leaderinme.org/research-highlights-academics/Starring: Kim Yaris, M.Ed, Content Creator/Researcher at FranklinCovey Education Dr. Jennifer Chevalier, Director of Funding at FranklinCovey EducationTime stamps: (00:00 - 00:25) Introduction(00:26 - 04:06) What is Systemic Synergy?(04:07 - 07:12) Improving Outcomes for Everyone(07:13 - 09:29) Maintaining Systemic Synergy(09:30 - 10:57) A Tool to Align Vision(10:58 - 12:26) Looking to the Future(12:27 - 12:51) Closing

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HERE---Episode Overview: How can we transform musculoskeletal care to improve outcomes and reduce costs? Our next guest, Rob Cohen, is tackling this challenge and more as CEO of Livara Health. With over two decades of healthcare leadership experience, Rob brings a unique perspective on value-based care and population health management. Previously leading companies like Bamboo Health and Evolent Health, Rob witnessed firsthand the transformative impact of innovative healthcare solutions. While together, Rob shares why he is driven by a passion to make healthcare more connected and sustainable and his vision to reimagine musculoskeletal management through comprehensive care planning, delivery, and navigation. Join us to discover how Livara's purpose-built solutions are enhancing patient experiences, optimizing clinical outcomes, and driving down costs for health plans and providers. Let's go! Episode Highlights:Emphasizes improving healthcare by building on existing strengths rather than total disruptionAddresses musculoskeletal (MSK) spend challenge: $400 billion annually, growing twice as fast as general healthcareOffers comprehensive MSK care: planning, navigation, and delivery to reduce unnecessary proceduresReports significant outcomes: 45% cost reduction, 35% fewer surgeries, 60% less opioid usePredicts future trend: integration of specialty value-based care programs for cohesive patient careAbout our Guest: Rob Cohen is the CEO of Livara Health, a value-based musculoskeletal (MSK) management company providing care planning, care delivery and care navigation to improve outcomes and lower costs for people with MSK conditions.Prior to joining Livara, Rob was the CEO at Bamboo Health, where he led the company's national expansion from 25 states to 45 states and was responsible for rapid revenue growth in new product lines and new market segments. Prior to Bamboo, Rob served as Market President at Evolent Health where he was responsible for market growth and managed the P&L and operations for partnerships with health systems. Prior to Evolent, Rob held leadership roles with Healthways, Wellpoint, The Walt Disney Company, and McKinsey & Company.He is a firm believer in the power of healthcare as a catalyst for positive change and is committed to making a meaningful difference in the lives of others.Links Supporting This Episode:Livara Health Website: CLICK HERERob Cohen LinkedIn page: CLICK HERELivara Health LinkedIn page: CLICK HERE Mike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form:

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, and guests Michael Cameron, MD, and James Allred, MD, discuss the intersection of GLP-1 agents and dermatology, exploring how these drugs, initially designed for managing type 2 diabetes, are now offering promising benefits for skin conditions associated with obesity. They begin by providing an overview of glucagon-like peptide-1 (GLP-1) agents and their mechanisms of action. These drugs, which include terzepitide (marketed as Mounjaro and Zepbound) and semaglutide (available as Ozempic and Wegovy), are GLP-1 receptor agonists that enhance insulin secretion, reduce appetite, and promote weight loss. Dr Allred then shares his personal experience, noting that patients on GLP-1 therapy, prescribed by their primary care physicians, showed remarkable improvements in their hidradenitis suppurativa (HS) symptoms. Observing these benefits, he began prescribing GLP-1 agents himself. Although randomized controlled trials directly linking GLP-1 agents to HS improvement are lacking, clinical observations align with the understanding that obesity-related systemic inflammation impacts dermatologic conditions like HS and psoriasis. The conversation then shifts to discussing weight management with patients. They stress the importance of empathy and understanding, particularly for patients with HS who may find exercise counterproductive due to flare-ups. By explaining that reducing systemic inflammation through weight loss can significantly improve HS symptoms, they find patients more receptive to GLP-1 therapy. Finally, they cover the practical aspects of integrating GLP-1 prescribing into dermatologic practice. Drs Allred and Cameron advise on patient assessment, including checking BMI and potential contraindications like a history of thyroid cancer. They highlight the importance of monitoring basic labs, such as glucose, hemoglobin A1c, and lipid profiles, to track the therapy's impact and support insurance approvals. Tune in to learn how dermatologists can leverage GLP-1 agents to improve patient outcomes by addressing the inflammatory underpinnings of conditions like HS and enhancing overall quality of life.

Shifting Your Mindset for Success with Dr. Lorenka Joseph, PharmD on 'This Week in Pharmacy' -- It's June 21st, 2024, and it's the Summer Solstice, the Longest Day of the Year occurring when one of Earth's poles is tilted toward the sun at its most extreme angle, and due to Earth's tilt, this happens twice a year.  Thanks to RxMile for sponsoring today's TWIRx, logistics strategies and technology, this software sells itself. With the expansion of long term care at home, and the need for more pharmacy delivery in areas with pharmacy closures, it's time to talk with Kunal and his team. This is a game changer.  NEWS: The New York Times reported on the impact to public health of the PBMs middlement, causing massive struggles for pharmacy care throughout the nation.  Pharmacy closures in Michigan and Ohio causing major concerns for the needs of millions of people.  Maternal Health Disparities, Role of Pharmacists in Improving Outcomes, from Pharmacy Times, interview with Rebeca Snead, PharmD.  Our feature interview with Dr. Lorneka Joseph PharmD, helping healthcare professionals Shift Your Mindset for Success! 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Efficiency in healthcare, like closing care gaps and reducing readmissions, is vastly improved through technological innovation. In this episode, Saul Marquez interviews Yoni Shtein, CEO of Laguna Health, a company revolutionizing care management through automation and technology with a mission to empower care managers with conversational intelligence. By leveraging natural language processing and AI, Laguna streamlines documentation, allowing care managers to focus on patients rather than paperwork, an innovation that, according to Yoni, not only enhances efficiency but also improves patient outcomes, reducing readmissions and optimizing care transitions. He also emphasizes Laguna's unique data set and language model, which differentiate the company in the market. Yoni highlights the significant ROI opportunities for payers, including increased efficiency, effectiveness, and cost savings, and challenges leaders to embrace nuanced thinking in navigating healthcare technology trends to drive better outcomes for patients.  Tune in and learn why building scalable solutions that deliver tangible value to consumers is paramount in today's healthcare landscape! Resources:  Watch the entire interview here. Follow and connect with Yoni Shtein on LinkedIn. Learn more about Laguna Health on their LinkedIn and website.

Send us a Text Message.Dr. Trillitye Paullin is a molecular biologist and founder of Free to Feed, a consultation service for navigating infant food reactivity in breastfeeding dyads. Today, Dr. Trill joins us with one of her clients, Chelsea, a first-time mom who found Trill and our podcast and reached out to help spread the research around newborn food reactivity. Trill shares her ground-breaking research into why and how a mother's diet causes allergic responses in babies in the form of bloody stools, skin rashes, vomiting, reflux and colic-like symptoms. With around 25% of parents reporting food allergy symptoms in their babies, these issues have been grossly underserved and misunderstood for decades. We cover: The top 12 foods causing allergy symptoms;The timing of protein transfer, reactivity, and gut healing;How our gastrointestinal health impacts infant food allergies;How stress and cortisol impact the transfer of proteins into milk.Stanford University and Free to Feed have embarked on a transformative partnership to develop tools aimed at accurately identifying and managing pediatric food allergies. This collaboration, part of the "Improving Outcomes for Food-Allergic Children" project led by Dr. Trillitye Paullin and supported by Stanford's Data Science for Social Good Program, seeks to enhance care quality while preventing unnecessary dietary restrictions for children. By integrating these tools into clinical practice and fostering enhanced awareness among providers, the initiative promises to improve health outcomes for children and provide significant insights into the complexities of food allergies, shaping future policies in pediatric healthcare.**********Down to Birth is sponsored by:Vitality: An athleisure brand made for women, by women, designed with style and comfort for pregnancy and beyond.Davin & Adley-- The perfect nursing and pumping bra combinedSilverette Nursing Cups -- Soothe and heal sore nipples with 925 silver nursing cups.Postpartum Soothe -- Herbs and padsicles to heal and comfort.Needed -- For before, during, and after pregnancy.Use promo code: DOWNTOBIRTHDrinkLMNT -- Purchase LMNT with this unique link and get a free 8-day supply.Connect on Patreon for our exclusive content.Email Contact@DownToBirthShow.comInstagram @downtobirthshow802-GET-DOWNWork with Cynthia:203-952-7299HypnoBirthingCT.comWork with Trisha:734-649-6 Connect with us on Patreon for our exclusive content.Email Contact@DownToBirthShow.comInstagram @downtobirthshowCall us at 802-GET-DOWN Work with Cynthia: 203-952-7299 HypnoBirthingCT.com Work with Trisha: 734-649-6294 Please remember we don't provide medical advice. Speak to your licensed medical provider for all your healthcare matters.

In this episode, join us as we explore how AI is revolutionizing how nurses approach patient assessments and diagnostic processes. Our guests, Stephanie H. Hoelscher, DNP, RN, NI-BC, CHISP, CPHIMS, FHIMSS, director of MSN Informatics, and Grace H. Sun, DNP, APRN, FNP-BC, associate professor in the MSN and DNP Nurse Practitioner Program at Texas Tech University Health Sciences Center, provide expert insights into the current state of AI in healthcare, issues and risks, and its direct implications for nursing practice. Discover how AI algorithms analyze vast amounts of patient data to detect patterns, predict outcomes, and support clinical decision-making. Whether you're a seasoned nurse looking to stay updated on the latest advancements in healthcare technology or a nursing student eager to learn about the intersection of AI and patient care, this episode offers valuable insights into the evolving role of AI in nursing practice.

This week's guest is in the business of maximizing outcomes.A self-described "reformed investment banker", Daniel Etra is the co-founder and CEO of Rethink, a data-driven company changing the face of neurodivergent care.He talks passionately about the vast social impact of their operations, teaching frontline clinicians, empowering caregivers, and helping neurodivergent individuals reach their potential.With their library of educational videos, cutting-edge Al tools and enormous dataset, Rethink are a modern company with global aims - centering inclusion and empowerment at the core of their ethos.Let's get started!Follow me on Instagram and Facebook @ericfethkemd and checkout my website at www.EricFethkeMD.com. My brand new book, The Privilege of Caring, is out now on Amazon! https://www.amazon.com/dp/B0CP6H6QN4

In this episode, Tim talks to the acclaimed osteopath and PhD candidate, Alison Sim about her research on preventing chronic pain after injury, particularly in the context of compensable care. Alison discusses the stressful and distressing nature of the compensation claim process, which can significantly impact recovery. Her research reveals an overlap in frustrations experienced by both claimants and clinicians, particularly regarding delays in care and lack of support. Alison's team developed a beneficial 5-session telehealth intervention based on co-design workshops with claimants. Interviews with experienced clinicians highlighted a common pattern of initial feelings of being underskilled, seeking further education, and ultimately developing a sense of mastery in their role. Alison suggests improvements to the compensation system, including early access to high-quality care and streamlining the claims process. Her research emphasises the importance of addressing psychosocial aspects of injury recovery in compensable care settings to foster better outcomes for individuals.   Keywords chronic pain, compensable care, claims process, early interventions, pain self-management, social support, clinician experience, complexity, uncertainty   Takeaways The claims process in compensable care can be distressing for both claimants and clinicians, and it is a significant predictor of poor outcomes. Early interventions that provide information about the claims process, pain self-management strategies, and social support can help improve outcomes for claimants. Experienced clinicians working in compensable care can find fulfillment and a sense of mastery in managing complexity and uncertainty. Improving access to high-quality care, enhancing communication skills, and providing support for both claimants and clinicians are essential for better outcomes in compensable care. Further research and evaluation are needed to assess the impact of interventions and systemic changes in compensable care. Sound Bites "I am interested in looking at early interventions to prevent the development of chronic pain following injury and particularly interested in injury in the setting of compensable care." "The distress of interacting with the processes required to engage with a claim is a big predictor of poor outcomes." "People didn't understand the claims process and felt overwhelmed by it." Chapters 00:00 - Introduction and Background 02:07 - PhD Research on Early Interventions in Compensable Care 08:19 - The Distressing Nature of the Claims Process 11:16 - Intervention: Providing Information, Self-Management Strategies, and Social Support 29:18 - Improving Outcomes in Compensable Care   Useful Links Le Pub Website: www.lepubscientifique.com  Become a Le Pub member: https://www.lepubscientifique.com/premium-membership  Contact us: lepubscientifique@gmail.com   Follow us: Twitter: @lepubscientifiq Instagram: @lepubscientifique LinkedIn: @LePubScientifique Join the Le Pub Community on Facebook: Le Pub Scientifique 

CME credits: 0.25 Valid until: 29-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-outcomes-and-addressing-racial-disparities-in-patients-with-hrher2-early-breast-cancer-a-case-based-learning-lab/16199/ The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (eBC) setting in combination with adjuvant endocrine therapy. In this educational activity, expert faculty review a clinical case series highlighting the application of CDK4/6 inhibitors in HR+/HER2− eBC, including identification of patients at high risk of recurrence/progression, selection of adjuvant therapy based on the latest clinical evidence and patient-specific factors, and management of treatment-related adverse events. Approaches to recognizing and addressing racial/ethnic health disparities among minority patients will also be discussed, empowering clinicians to make informed decisions that align with achieving health equity. =

How can we provide culturally safe care for patients with schizophrenia who are members of underserved communities? Credit available for this activity expires: 4/26/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000734?ecd=bdc_podcast_libsyn_mscpedu

Learn how to inspire and improve outcomes for disproportionately impacted college students. Continuous Learning InstitutePractical and actionable strategies for college educators to improve student success.Student Success Podcast HomepageAccess show notes & transcripts

Welcome back to Highest Aspirations, an education podcast focused on providing educators with inspiration and strategies to help multilingual learners achieve their highest aspirations. In this episode, we zoom out some to talk about what happens after multilingual learners and other students from marginalized communities leave K-12 schools and what we can do to ensure they are equipped to rewatch their highest aspirations. Our guest David Nungaray and I talk about… What the data says about economic and social mobility of students from historically marginalized communities How we can help improve outcomes and long-term trajectories of students from historically marginalized communities, including multilingual learners And how we can we leverage the linguistic and cultural assets MLs bring to better our communities while simultaneously working to close wealth gaps For the full episode transcript, click here. For additional resources and to find information about the 2024 Ellevation Scholarship that is now open, visit our EL Community blog. David Nungaray is the Bilingual Consulting Partner at TNTP. Currently, David oversees partnerships in Alaska, California, Nevada, and Texas. He also supports TNTP's multilingual strategy across the country. David has led teams focused on partnering with districts through strategic planning, (bi)literacy visioning and implementation, dual language supports, stakeholder and family engagement, high-impact tutoring, learning acceleration, and state-wide high-quality instructional materials adoption. Prior to his time at TNTP, David served as the principal of one of the flagship dual language schools in San Antonio ISD. He first began his career as a dual language teacher and has led work in bilingual education for over a decade. As a son of immigrants, native Spanish speaker, and a first-generation college graduate, David is passionate about educational equity and to ensuring school systems best meet the needs of all learners. David is also an alum of Teach For America. He serves on multiple non-profit boards focused on education, and he holds his Masters in School Leadership from Trinity University, where he has served as an adjunct professor in multilingual education, school leadership, and special education. He also recently co-authored a chapter in "Breaking Down the Monolingual Wall" that speaks to essential shifts needed in leadership to support multilingual learners.  --- Send in a voice message: https://podcasters.spotify.com/pod/show/highest-aspirations/message

In this episode of the Leading Voices podcast, host Danny Torres talks with Angela McGuire, Project Director within WestEd's Early Childhood Intervention, Mental Health, and Inclusion team under Early Childhood Development and Learning. Angela leads the Comprehensive Early Intervention Technical Assistance Network (CEITAN), which has supported the professional growth of early childhood intervention professionals for more than 30 years. Together, they discuss the critical role of early intervention in improving outcomes for our youngest children with disabilities and how state agency leaders can best support early intervention professionals in their work. Their conversation covers the following topics: What state leaders need to know to best support early intervention professionals The Comprehensive Early Intervention Technical Assistance Network (CEITAN) work in California The relationships between parents or caregivers and professionals in early intervention work How early intervention professionals help prepare families as their children move into the K-12 system Workforce development and capacity building for early intervention professionals Transcript Additional Resources Transforming Early Intervention and Improving Outcomes for Children—Q&A with Angela McGuire (Blog Post) Cultural Humility Series (Webpage) Early Childhood Development, Learning, and Well-Being (Webpage) California Early Start (Webpage)

President of the Greater Milwaukee Committee Joel Brennan joins Wisconsin's Midday News to provide his thoughts on the passing of the MPS referendum on Tuesday. Joel discusses ways MPS and the community can work together to improve outcomes for MPS students going forward. Brennan also talks about Milwaukee's plans to redesign Michigan Street.

Host Kyle B. Enfield, MD, FSHEA, FCCM is joined by Danielle K. Maue, MD, to discuss improving outcomes for bronchiolitis patients through a high-flow nasal cannula protocol, as discussed in the Pediatric Critical Care Medicine article, "Improving Outcomes for Bronchiolitis Patients After Implementing a High-Flow Nasal Cannula Holiday and Standardizing Discharge Criteria in a PICU." (Maue DK, et al. Pedtr Crit Care Med. 2023 Mar;24:233-244). Together, they explore groundbreaking initiatives that significantly improved outcomes for bronchiolitis patients using a high-flow nasal cannula protocol, the key interventions, and their impact. Dr. Maue is an Assistant Professor of Clinical Pediatrics for Riley Hospital for Children at Indiana University in Indianapolis, Indiana.

Dr. Chuck Thigpen, Senior Vice President for Clinical Excellence at ATI, as we talk about the pivotal role of physical therapy in healthcare. We explore the Department of Defense's recent acknowledgment of physical therapists as primary care providers and what it means for the future of musculoskeletal (MSK) care.We had to start by congratulating Chuck on his recent induction into the Academy of Sports Physical Therapy Hall of Fame.Key Message:Physical therapy stands at the forefront of healthcare for MSK pain, offering a fundamental and essential approach to overall health akin to primary care. With the military setting a precedent, it's time to recognize and utilize PT for its safe, effective, and cost-efficient benefits in the general population.Supporting Points: Safety and Efficacy of PT: Discover how physical therapy serves as a reliable and effective first course of treatment for MSK issues, setting the stage for a healthier future. Improving Outcomes and Reducing Costs: Learn about the tangible benefits of choosing PT first, including enhanced patient outcomes and significant cost savings in healthcare. Military Endorsement as a Benchmark: If the military, with its rigorous standards and focus on optimal performance, trusts in PT as a primary care solution, why shouldn't we? Explore how this endorsement is a game-changer for public healthcare perceptions.Opportunity to Lead: This episode also highlights ATI's leadership in the physical therapy profession, demonstrating the organization's commitment to advancing healthcare. From the vast resources and experience ATI harnesses to deliver unparalleled care, to creating an engaging and supportive work environment, discover why ATI is not just a leader in physical therapy but also an exemplary place to work and collaborate.Chuck also gives more insight on a recent announcement from ATI on the topic of expanding research reach, ATI unveiled iMSKA, "iMSKA is dedicated to progressing quality clinical care with a focus on research. The institute was established to offer long-lasting and ongoing contributions to the growing body of scientific knowledge and evidence in the management of patients with MSK conditions." More information here, https://i-mska.org/Dr. Thigpen brings a wealth of knowledge, backed by his extensive experience and the innovative practices at ATI, to shed light on how direct access to physical therapy is reshaping healthcare for the better. Whether you're a healthcare professional, someone experiencing MSK pain, or simply interested in the future of healthcare, this episode offers valuable insights into the evolving landscape of physical therapy as a primary care service.Have you ever thought about where your career in physical therapy could take you? It's not just about the job; it's about making real connections that help patients get better faster. Imagine working somewhere you can grow through mentorship, and get leadership training that matters.Sounds like a place you'd fit right in? Click to find out more about what working with ATI is really like. And let's make a difference together.

CME credits: 1.00 Valid until: 14-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/improving-outcomes-in-patients-with-rvo-tailoring-treatment/16626/ Dr. Carl Danzig, Director of Vitreoretinal Services and Retina Clinical Research of Rand Eye Institute in Deerfield Beach, Florida, and Dr. Arshad Khanani, Clinical Associate Professor at the University of Nevada in Reno, Nevada, will present key data about anti-VEGF therapies for retinal vein occlusion (RVO). Join the discussion on developing treatment protocols that use current therapies most effectively to improve outcomes and individualized treatment protocols for patients who are nonresponsive to first-line therapies and who require chronic treatment for macular edema.=

Joining host Chadi is a trio of esteemed guests – Drs. Andy Evans, Matt Maurer, and Susan Parsons – of the HoLISTIC (Hodgkin Lymphoma International Study for Individual Care) Consortium. In this riveting conversation, they delve into the consortium's pioneering efforts, bringing together an international team of experts to scrutinize the multifaceted dimensions of Hodgkin lymphoma, spanning prognosis, epidemiology, treatment, survivorship, and health outcomes across all age groups. The discussion circles around consensus protocols for treatment, referral pathways, and clinical trials, probing the necessity of transplants in the era of novel therapeutics and the creation of predictive models tailored to individual patient needs. Tune in to hear about the meticulous efforts invested in building the HoLISTIC portal, automating data migration, and navigating the challenges and progress in predictive modeling for treatment selection, response, and failure. This episode offers a captivating exploration of how collaboration, technology, and data analysis converge to shape the future of Hodgkin lymphoma care. Find out more about the HoLISTIC Consortium. https://www.hodgkinconsortium.com/ Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Event Objectives:Identify the current status of circumcision circumcision complications and need for surgical repair of newborn circumcision in the US.Understand the reasons behind the rising rate of newborn circumcision surgical repair in the US.Outline strategies to overcome the reasons for newborn surgical circumcision repair and improve the quality and safety of newborn circumcisions performed.Claim CME credit here!

On today's show we interviewed Amanda Saylor and Becca Carr, aka @neuro_OTs on Instagram, about an exciting, relatively new piece of technology advancing outcomes for stroke survivors called Vivistim. This device is the first FDA approved implantable device for rehab for upper extremity recovery. It was approved in August 2021 and is being used in many cities across the US for people with chronic, ischemic stroke in addition to intensive therapy. In the show you'll learn: The results of the randomize, placebo controlled triple blind study that paved the way for the FDA approval How the device works Who it's indicated for and who it is not approved for How it's intended to be used (Hint: THERAPY must be involved) and what that looks like Case study data How people can get one Is it approved by insurances and Medicare? (Spoiler: You'll be happy to hear it is!) The improvements clients are making with the device are incredible! Clients who were slowing or halted in the progress of their upper limb function are making massive improvements in their functional movement with the implantable device paired with intensive occupational therapy. Learn more and spread the word so more people can benefit from the advancements in rehab. Learn more: https://www.vivistim.com ACRM_VivistimPoster Lancet MicroTransponder Follow @neuro_OTs and @yourotmentor on Instagram for more helpful tips!

CME credits: 0.75 Valid until: 09-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-management-of-menopausal-symptoms-improving-outcomes-with-individualized-therapy/16532/ Understanding the physiologic basis for the vasomotor symptoms of perimenopause/menopause has led to an improved ability to match a therapeutic approach to each individual patient. New and improved agents are helping to facilitate this dynamic. Join Anita Nelson, MD, and Barbara Dehn, NP, as they provide insights into making the right treatment decision for each patient—one that includes ensuring patient preferences are considered.=

For a full transcript of this episode, click here. I want to kick off this show with a clip from episode 415 with Rob Andrews, wherein he so very eloquently sets the stage here: We think that one of the core problems here is that too many intermediaries and providers in the system, their compensation is not in any way dependent on the outcome. So, let's think about this NICU baby problem again. Looking at the hospital system—and I'm not at all implying or suggesting any hospital system tries to do this—but I think it is clear that they actually benefit commercially from more babies spending more days in the NICU. NICU's usually a pretty good margin business. It's expensive. Lots of money is paid, and margins run pretty well there. So, I don't think there's a hospital system in the country that intentionally says, “Oh, good … let's go out and try to fill up the NICU every day.” But when it gets filled up, they benefit. On the other hand, if the hospital invests significantly in early effective intervention prenatal or even pre-pregnancy, there's no upside to that financially. They don't get rewarded for that. They might win an award from some magazine for best practices, but their margin suffers. Then if you look at the intermediaries, the carriers, and PBMs [pharmacy benefit managers], their outcomes are irrelevant to their performance. If an employee of a self-insured employer has a significant risk prenatal or pre-pregnancy and the carrier does a great job identifying that problem and solving it, they make the same amount of money off that patient or that consumer that they would if they did nothing. So, it's a bit harsh to say this, but the carriers make the same amount of money if every child is born healthy and there's not a day spent in the NICU as if they do if every child's born with severe crises and winds up in the NICU. It's not a big mystery in the US economy that people do what you pay them to do. And if you have a system, which we do now, where the case of maternal health, diabetes management, musculoskeletal management, cholesterol and cardiac management … when you have a system where many, many players in the system, at best, make the same amount of money for bad outcomes as they do for good ones and, at worst, they prosper from the bad outcomes, that explains the problem. So, is this show about improving maternal health outcomes in the US, where it is relatively deadly to have a baby compared to other industrialized nations? Yes. But improving maternal health is also a great case study for what needs to be done to just improve health. You could apply it to primary care. You could apply it to chronic care management. It is a fairly broad-spectrum solution, as it were. I'm thinking right now about how Dave Chase, co-founder of Health Rosetta—how does he put it?—he says every big problem in healthcare already has been solved. The existing challenge is how to massively replicate proven solutions. So, yeah … keep that in mind when we talk about what Jodilyn Owen has accomplished with her team in Washington State with their birth and health center. Also, as you consider how you might replicate, keep in mind the struggles she has faced getting contracts from self-insured employers or payers to pay her clinic and a very interesting encounter she had with a VC/PE (venture capital/private equity) funded maternal health start-up. It's just interesting where the money is flowing and where it's not flowing. But let's talk about Jodilyn's clinic's outcomes. Their zip code is one of the most diverse in the nation. There are 79 languages spoken. There is lots of social determinants of health going on. It is a medically underserved area. It is a federally designated provider shortage area. So, this community has every right to have horrible outcomes. Meanwhile, nearby, there is a wealthy community. In that zip code, they live 17 years longer than in Jodilyn's clinic's zip code. But if you compare the outcomes that Jodilyn's clinic has compared to the outcomes in the hospital in that fancy neighborhood, Jodilyn's group has far less cesarean rates, far less NICU admissions, far less incidence of gestational diabetes, far quicker access to treatment for hypertension. You might be wondering how much their birth bundle costs that they are having trouble getting most payers except one to pay for and getting no VC dollars or funding at all. They're charging $5000 to $7000. So, let's just say $5000 to $7000 compared to … what does one NICU admission cost? So, yeah … this is an exact example of what Rob Andrews was talking about. An EXACT example. So yeah, enjoy this episode; it's as heartwarming and actionable as it is frustrating. And if you are a payer or self-insured employer in South Seattle, please give this clinic a contract. Not to drop a major spoiler alert here, but you know what Jodilyn's “secret sauce” is? Nuances for sure, but bottom line, it's about trust. It's about relationships. It's about listening to the patient. It's being part of the local community. If you're shocked right now, raise your hand. There's gonna be no one with their hand raised. How many times do we have to figure this out? Jodilyn Owen is the clinical director of the Rainier Valley Birth & Health Center. She is a licensed midwife along with a bunch of other credentials. Also mentioned in this episode are Rob Andrews; Dave Chase; Vivek Garg, MD, MBA; and Larry Bauer.   You can learn more by emailing Jodilyn at jodilyno@myrvcc.org. You can also connect with her on LinkedIn.   Jodilyn Owen, LM, CPM, Ma MCHS, is a licensed, certified professional midwife and co-founder of Rainier Valley Birth & Health Center. She was born and raised in Seattle and raised her own family in South Seattle, working as a doula and parenting educator for 13 years before becoming a midwife. This is where she saw healthcare through the lens of observation of hundreds of families and provider experiences of maternal and child healthcare. An avid learner and critical thinker, Jodilyn began to reimagine healthcare and to develop a vision for what access in its truest form might be, not just to healthcare for the deeply underserved and mis-served families of South Seattle but also to quality healthcare delivery for the providers who want to give more than what the system allows. Jodilyn built her practice around the idea that parents know themselves and their babies best, and her direct patient work is designed to promote this first relationship. She provides individualized, gentle, and holistic pregnancy, birth, and postpartum care for families planning a home, birth center, or hospital birth. Jodilyn is currently director of clinical partnerships and staff midwife at the nonprofit–for purpose Rainier Valley Birth & Health Center. She provides infrastructure development, guides clinical programs and partnerships, and supports students from multiple university health professions and public health programs at all levels from high school through doctoral studies.   07:12 How much cost savings is there when you avoid a NICU admission? 09:43 How is “slow care” feasible among an ob-gyn shortage in many communities? 10:42 “Start people at the risk that they are appropriate for.” 11:37 EP407 and Summer Shorts 3 with Vivek Garg, MD, MBA. 13:50 “To effect change, we have to unwind what has been wound so tightly and so carefully through medical … education.” 14:13 “It's not a people problem; it's a system problem.” 18:46 What does relationship-based care mean? 22:32 “Everything in pregnancy at least is a trend.” 28:01 How does Jodilyn's practice work with payers? 31:08 EP409 with Larry Bauer, MSW, MEd. 32:24 Why is it important to address the root of this problem in the education space?   You can learn more by emailing Jodilyn at jodilyno@myrvcc.org. You can also connect with her on LinkedIn.   @essntialmidwife discusses improving maternity #patientoutcomes in our #healthcarepodcast. #healthcare #podcast #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Ge Bai, Andreas Mang, Karen Root (Encore! EP381), Mark Cuban and Ferrin Williams, Dan Mendelson (Encore! EP385), Josh Berlin, Dr Adam Brown, Rob Andrews, Justina Lehman, Dr Will Shrank  

Dina Tyler's FANTASTIC, heartful, brilliant December 2023 Grand Rounds talk at UCSF Medical School, “Improving Outcomes for Psychosis: Psychiatric Survivor and Critical Psychiatry Perspectives.” Also available as a video. (Transcript) (Slides from talk) www.dinatyler.com The post UCSF Grand Rounds | Dina Tyler | Madness Radio first appeared on Madness Radio.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRV865. CME/MOC/CPE/AAPA/IPCE credit will be available until November 9, 2024.Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLuke Maese, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Jazz Pharmaceuticals.Speaker for Jazz Pharmaceuticals.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRV865. CME/MOC/CPE/AAPA/IPCE credit will be available until November 9, 2024.Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLuke Maese, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Jazz Pharmaceuticals.Speaker for Jazz Pharmaceuticals.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRV865. CME/MOC/CPE/AAPA/IPCE credit will be available until November 9, 2024.Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLuke Maese, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Jazz Pharmaceuticals.Speaker for Jazz Pharmaceuticals.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRV865. CME/MOC/CPE/AAPA/IPCE credit will be available until November 9, 2024.Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLuke Maese, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Jazz Pharmaceuticals.Speaker for Jazz Pharmaceuticals.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRV865. CME/MOC/CPE/AAPA/IPCE credit will be available until November 9, 2024.Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLuke Maese, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Jazz Pharmaceuticals.Speaker for Jazz Pharmaceuticals.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Guest: Dawn Kimberly Hopkins, PhD, WHNP-BC Understanding the manifestations of polycystic ovary syndrome (PCOS) can help to identify this condition in women better. And though it's a common condition, some providers are unaware of how to diagnose it. Dig into the pathophysiology of PCOS with Dr. Dawn Kimberly Hopkins, Research Associate at the Henry Jackson Foundation in Bethesda, Maryland.

Go online to PeerView.com/HXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite significant strides made in the surgical management of resectable NSCLC, a considerable proportion of patients face an unacceptably high risk of recurrence and poor sequelae. The swift expansion of immunotherapy into the early-stage, resectable, curative-intent setting offers them new hope, as FDA approvals in the adjuvant and neoadjuvant settings reshape standards of care and ongoing clinical trials continue to expand the role of immunotherapy-based options into this setting as well. But what do these developments mean for thoracic surgeons and the other members of the multidisciplinary lung cancer care team? How should the care team work together to utilize best practices and standards of care to guide individualized treatment selection and make the most of new immunotherapy options? This PeerView educational activity, based on a recent live symposium, addresses these questions and considers the expanding role of immunotherapies in resectable NSCLC by bringing together leading experts to evaluate the new, practice-changing research and offer a practical framework that improves interdisciplinary alliances and workflows with the goal of integrating immunotherapies into treatment plans to expand their benefits to as many patients with resectable NSCLC as possible. Are you ready to take your practice to the next level with perioperative immunotherapy? Upon completion of this activity, participants should be better able to: Assess the existing evidence guiding the use of neoadjuvant and adjuvant immunotherapy in stage I-III resectable NSCLC, including rational designs for clinical trials, novel endpoints, efficacy, safety, surgical outcomes, and other essential data; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Integrate neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making.

Go online to PeerView.com/HXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite significant strides made in the surgical management of resectable NSCLC, a considerable proportion of patients face an unacceptably high risk of recurrence and poor sequelae. The swift expansion of immunotherapy into the early-stage, resectable, curative-intent setting offers them new hope, as FDA approvals in the adjuvant and neoadjuvant settings reshape standards of care and ongoing clinical trials continue to expand the role of immunotherapy-based options into this setting as well. But what do these developments mean for thoracic surgeons and the other members of the multidisciplinary lung cancer care team? How should the care team work together to utilize best practices and standards of care to guide individualized treatment selection and make the most of new immunotherapy options? This PeerView educational activity, based on a recent live symposium, addresses these questions and considers the expanding role of immunotherapies in resectable NSCLC by bringing together leading experts to evaluate the new, practice-changing research and offer a practical framework that improves interdisciplinary alliances and workflows with the goal of integrating immunotherapies into treatment plans to expand their benefits to as many patients with resectable NSCLC as possible. Are you ready to take your practice to the next level with perioperative immunotherapy? Upon completion of this activity, participants should be better able to: Assess the existing evidence guiding the use of neoadjuvant and adjuvant immunotherapy in stage I-III resectable NSCLC, including rational designs for clinical trials, novel endpoints, efficacy, safety, surgical outcomes, and other essential data; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Integrate neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making.

Go online to PeerView.com/HXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite significant strides made in the surgical management of resectable NSCLC, a considerable proportion of patients face an unacceptably high risk of recurrence and poor sequelae. The swift expansion of immunotherapy into the early-stage, resectable, curative-intent setting offers them new hope, as FDA approvals in the adjuvant and neoadjuvant settings reshape standards of care and ongoing clinical trials continue to expand the role of immunotherapy-based options into this setting as well. But what do these developments mean for thoracic surgeons and the other members of the multidisciplinary lung cancer care team? How should the care team work together to utilize best practices and standards of care to guide individualized treatment selection and make the most of new immunotherapy options? This PeerView educational activity, based on a recent live symposium, addresses these questions and considers the expanding role of immunotherapies in resectable NSCLC by bringing together leading experts to evaluate the new, practice-changing research and offer a practical framework that improves interdisciplinary alliances and workflows with the goal of integrating immunotherapies into treatment plans to expand their benefits to as many patients with resectable NSCLC as possible. Are you ready to take your practice to the next level with perioperative immunotherapy? Upon completion of this activity, participants should be better able to: Assess the existing evidence guiding the use of neoadjuvant and adjuvant immunotherapy in stage I-III resectable NSCLC, including rational designs for clinical trials, novel endpoints, efficacy, safety, surgical outcomes, and other essential data; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Integrate neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making.

Go online to PeerView.com/HXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite significant strides made in the surgical management of resectable NSCLC, a considerable proportion of patients face an unacceptably high risk of recurrence and poor sequelae. The swift expansion of immunotherapy into the early-stage, resectable, curative-intent setting offers them new hope, as FDA approvals in the adjuvant and neoadjuvant settings reshape standards of care and ongoing clinical trials continue to expand the role of immunotherapy-based options into this setting as well. But what do these developments mean for thoracic surgeons and the other members of the multidisciplinary lung cancer care team? How should the care team work together to utilize best practices and standards of care to guide individualized treatment selection and make the most of new immunotherapy options? This PeerView educational activity, based on a recent live symposium, addresses these questions and considers the expanding role of immunotherapies in resectable NSCLC by bringing together leading experts to evaluate the new, practice-changing research and offer a practical framework that improves interdisciplinary alliances and workflows with the goal of integrating immunotherapies into treatment plans to expand their benefits to as many patients with resectable NSCLC as possible. Are you ready to take your practice to the next level with perioperative immunotherapy? Upon completion of this activity, participants should be better able to: Assess the existing evidence guiding the use of neoadjuvant and adjuvant immunotherapy in stage I-III resectable NSCLC, including rational designs for clinical trials, novel endpoints, efficacy, safety, surgical outcomes, and other essential data; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Integrate neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making.

Go online to PeerView.com/HXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite significant strides made in the surgical management of resectable NSCLC, a considerable proportion of patients face an unacceptably high risk of recurrence and poor sequelae. The swift expansion of immunotherapy into the early-stage, resectable, curative-intent setting offers them new hope, as FDA approvals in the adjuvant and neoadjuvant settings reshape standards of care and ongoing clinical trials continue to expand the role of immunotherapy-based options into this setting as well. But what do these developments mean for thoracic surgeons and the other members of the multidisciplinary lung cancer care team? How should the care team work together to utilize best practices and standards of care to guide individualized treatment selection and make the most of new immunotherapy options? This PeerView educational activity, based on a recent live symposium, addresses these questions and considers the expanding role of immunotherapies in resectable NSCLC by bringing together leading experts to evaluate the new, practice-changing research and offer a practical framework that improves interdisciplinary alliances and workflows with the goal of integrating immunotherapies into treatment plans to expand their benefits to as many patients with resectable NSCLC as possible. Are you ready to take your practice to the next level with perioperative immunotherapy? Upon completion of this activity, participants should be better able to: Assess the existing evidence guiding the use of neoadjuvant and adjuvant immunotherapy in stage I-III resectable NSCLC, including rational designs for clinical trials, novel endpoints, efficacy, safety, surgical outcomes, and other essential data; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Integrate neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making.

More than 2,000 New Haven kids need spots in daycare or Pre-K. A handful of offshore wind projects in New York get approval from the governor. Connecticut's judicial branch looks to expand diversity. And October is breast cancer awareness month.

Cardiac surgery is definitely its own specialty, and not all perioperative professionals are familiar with the CVOR. But we're all familiar with the fundamentals of infection prevention. Here to highlight the specifics of infection prevention in cardiac surgery is Ruth Statchura, MBA, RN, Vice President of Business Development at C Change Surgical. In this episode, we'll discuss some of the common areas of infection risk, how we can avoid increasing those risks, and we'll uncover the changes in cardiac surgery that are improving patient outcomes. Tune in now! Love our show? Download our First Case mobile app on:

This week our guest is Dr. Joyce Chang, MD, MSCE, a recipient of the Lupus Foundation of America's “Mary Betty Stevens Young Investigator Award”, who shares her latest study, its methods, conclusions and career journey with us! Dr. Chang's latest study “Improving Outcomes of Pediatric Lupus Care Delivery With Provider Goal-Setting Activities and Multidisciplinary Care Models“ used the pediatric Lupus Care Index (pLCI) and population management strategies for improving outcomes in childhood SLE. Later, we spent some time with Dr. Chang and asked what she sought out in her first faculty appointment and how she ensured she would hit the ground running.